CD86 and neoplasm: In tumor-draining lymph nodes (TDLNs), the proportion of CD86+CD11c+ DCs in the RCL@Pd@CuZ + RT group was 59.24% ± 1.21%, which was markedly higher than that in the RT group (43.14% ± 1.63%).